Saturday 17 October 2026
Export ADPT’s income statement to Excel — free account
Adaptive Biotechnologies Corporation
ADPT Healthcare Diagnostics & Research
Adaptive Biotechnologies Corporation’s revenue for fiscal 2025 (year ended December 2025) was $277.0 million, up 54.8% from fiscal 2024. In the quarter to June 2026, revenue grew 21.5%, EPS fell 47.1% and free cash flow grew 42.0%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
24.02
1.56
−6.10%
Follow ADPT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 6 | 6 | 5 |
+8 more TTM periods Free account |
| (38.68%) | (23.97%) | (27.84%) | (37.22%) | ||
| (11.23%) | (9.77%) | (11.31%) | (15.18%) | ||
ROIC |
(16.57%) | (494.38%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(17.62%) | (21.09%) | (24.35%) | (33.80%) | |
Average Days of Receivables |
58.66 | 59.70 | 66.37 | 64.73 | |
Free Cash Flow per Share |
(0.15) | (0.19) | (0.32) | (0.41) | |
Free Cash Flow |
(24.03) | (29.53) | (48.94) | (62.93) | |
Capital Expenditures |
(3.02) | (2.50) | (2.96) | (2.40) | |
| Other line items | |||||
Cash ROIC |
(2.90%) | (6.67%) | (10.83%) | (15.09%) | |
Accounts Receivable Turnover |
6.57 | 6.43 | 6.01 | 5.90 | |
Accounts Payable Turnover |
12.39 | 9.15 | 10.39 | 8.08 | |
Inventory Turnover |
7.96 | 7.35 | 7.82 | 6.50 | |
Average Days of Payables |
25.42 | 48.02 | 33.08 | 52.65 | |
Days of Inventory on Hand |
50.91 | 55.96 | 50.23 | 50.93 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
28.63% | 31.55% | 33.85% | 37.66% | |
Selling, General and Administrative Expense of Revenue |
58.55% | 58.95% | 60.39% | 64.44% | |
Share Based Compensation of Revenue |
15.91% | 17.35% | 18.59% | 20.41% | |
Interest Coverage |
(3.25) | (3.97) | (4.85) | (6.64) | |
Operating CF/Net income |
0.33 | 0.54 | 0.77 | 0.76 | |
Depreciation/Fixed assets |
0.51 | 0.50 | 0.45 | 0.38 | |
Capex/Depreciation |
(0.20) | (0.16) | (0.19) | (0.17) | |
Revenue per Share |
1.93 | 1.90 | 1.83 | 1.66 | |
Operating CF per Share |
(0.13) | (0.17) | (0.30) | (0.40) | |
Capex per Share |
(0.02) | (0.02) | (0.02) | (0.02) | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 |
Columns are period end dates